Literature DB >> 9357409

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.

R Turner1, I Stratton, V Horton, S Manley, P Zimmet, I R Mackay, M Shattock, G F Bottazzo, R Holman.   

Abstract

BACKGROUND: Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables.
METHODS: We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 white patients with type 2 diabetes, aged between 25 and 65 years. The phenotype was assessed by age of onset, body-mass index, percentage haemoglobin A1c (HbA1c), and islet beta-cell function. We investigated the need for insulin therapy among 1538 patients not assigned insulin and followed up for 6 years from diagnosis.
FINDINGS: The proportion of patients with ICA and GADA decreased with increasing age at diagnosis (from 33 [21%] of 157 patients aged 25-34 [corrected] to 66 [4%] of 1769 aged 55-65 for ICA; from 53 [34%] to 122 [7%] for GADA). Among patients younger than 35 at diagnosis, those with ICA or GADA had lower body-mass index than those without (mean 24.9 [SD 6.0] vs 31.7 [7.3] kg/m2; p < 0.0001 and had higher percentage of HbA1c (9.7 vs 8.7%, p < 0.05). 94% of patients with ICA and 84% of those with GADA required insulin therapy by 6 years, compared with 14% of those without the antibodies (p < 0.0001). Among patients older than 55 at diagnosis, the difference between those with and without antibodies in body-mass index was smaller (27.2 [5.4] vs 28.6 [4.8] kg/m2, p < 0.001); 44% of those with ICA, 34% of those with GADA, and 5% with neither antibody required insulin therapy by 6 years (p < 0.0001). Among patients older than 45 years, body-mass index and HbA1c provided little predictive information for insulin requirement, whereas the positive predictive values of GADA (> or = 60 U/L) alone, or both GADA (> or = 20 U/L) and ICA (> 5 U/L), for insulin therapy were 52% and 68%.
INTERPRETATION: Among young adults with type 2 diabetes, the phenotype of those with ICA or GADA antibodies was similar to that of classic juvenile-onset insulin-dependent diabetes, and either phenotype or antibodies predicted insulin requirement. In older adults, the phenotype was closer to that of patients without antibodies and only the presence of antibodies predicted an increased likelihood of insulin requirement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357409     DOI: 10.1016/s0140-6736(97)03062-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  146 in total

1.  Autoantibodies as predictors of disease.

Authors:  D Leslie; P Lipsky; A L Notkins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.

Authors:  J P Palmer
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Autoimmune type 1 diabetes: resolved and unresolved issues.

Authors:  A L Notkins; A Lernmark
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 4.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 5.  Type 1 diabetes: recent developments.

Authors:  Devasenan Devendra; Edwin Liu; George S Eisenbarth
Journal:  BMJ       Date:  2004-03-27

6.  Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes!

Authors:  O Rolandsson; J P Palmer
Journal:  Diabetologia       Date:  2010-03-25       Impact factor: 10.122

7.  Approach to the obese adolescent with new-onset diabetes.

Authors:  Philip Zeitler
Journal:  J Clin Endocrinol Metab       Date:  2010-12       Impact factor: 5.958

Review 8.  Epidemiology of type 1 diabetes.

Authors:  David M Maahs; Nancy A West; Jean M Lawrence; Elizabeth J Mayer-Davis
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

9.  How to diagnose and classify diabetes in primary health care: lessons learned from the Diabetes Register in Northern Sweden (DiabNorth).

Authors:  Olov Rolandsson; Margareta Norberg; Lennarth Nyström; Stefan Söderberg; Maria Svensson; Bernt Lindahl; Lars Weinehall
Journal:  Scand J Prim Health Care       Date:  2012-06       Impact factor: 2.581

10.  Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

Authors:  Jonathan Q Purnell; Raj K Dev; Michael W Steffes; Patricia A Cleary; Jerry P Palmer; Irl B Hirsch; John E Hokanson; John D Brunzell
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.